This novel pharmacological approach is based on the repositioning strategy of “CFTR correctors” developed to treat type II mutations of cystic fibrosis transmembrane-conductance regulator (CFTR) (e.g., F508del) causing cystic fibrosis [12]. Here, CFTR is linked to cystic fibrosis.